Trials / Unknown
UnknownNCT05903963
Evaluation of Renal Protection Of Dexmedetomidine Versus Midazolam As a Sedative For Septic Patients In Intensive Care Unit
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Minia University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of Renal Protection Of Dexmedetomidine Versus Midazolam As a Sedative For Septic Patients In Intensive Care Unit
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Midazolam | midazolam infusion by 0.03-0.3mg/kg in increments of 1-2.5mg followed by Maintenance dose: 0.03-0.2mg/kg/hour for midazolam. |
| DRUG | dexmedetomidine | dexmedetomidine infusion 1 µg/kg dexmedetomidine for 10 minutes followed by a continuous IV infusion at 0.2-0.3 µg/kg/hour . |
Timeline
- Start date
- 2023-05-22
- Primary completion
- 2023-11-12
- Completion
- 2023-12-20
- First posted
- 2023-06-15
- Last updated
- 2023-06-15
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05903963. Inclusion in this directory is not an endorsement.